Court Place Advisors LLC Sells 89 Shares of Pfizer, Inc. (PFE)
Court Place Advisors LLC cut its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,027 shares of the biopharmaceutical company’s stock after selling 89 shares during the period. Pfizer comprises 1.3% of Court Place Advisors LLC’s holdings, making the stock its 22nd largest position. Court Place Advisors LLC’s holdings in Pfizer were worth $2,688,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the stock. Northstar Group Inc. raised its stake in Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 35 shares during the period. Stone House Investment Management LLC raised its stake in Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 66 shares during the period. Naples Global Advisors LLC raised its stake in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 79 shares during the period. Pure Financial Advisors Inc. raised its stake in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 84 shares during the period. Finally, Alpha Windward LLC raised its stake in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 89 shares during the period. 69.09% of the stock is owned by institutional investors.
Pfizer, Inc. (NYSE:PFE) traded up 1.58% on Thursday, hitting $33.98. The company’s stock had a trading volume of 9,086,603 shares. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.18. The firm has a 50 day moving average of $33.25 and a 200 day moving average of $33.42. The firm has a market cap of $202.09 billion, a price-to-earnings ratio of 24.86 and a beta of 1.00.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the firm posted $0.64 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is 94.12%.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/court-place-advisors-llc-sells-89-shares-of-pfizer-inc-pfe/1534526.html.
A number of research firms have recently weighed in on PFE. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Morgan Stanley reissued a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Berenberg Bank set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and lowered their target price for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $37.61.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 120,014 shares of company stock valued at $4,062,493 in the last three months. 0.06% of the stock is currently owned by insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.